12:00 AM
Mar 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SparVax: Phase II data

Data from a double-blind Phase II trial in 415 volunteers showed that SparVax was safe and well tolerated. A significant response was seen in all 4 dosage groups when an antigenic challenge...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >